Study of Immediate Cisplatin and Gemcitabine Chemotherapy After Surgery for High-Risk Non-Muscle-Invasive Bladder Cancer
Led by Changhai Hospital · Updated on 2025-03-21
72
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and effectiveness of giving systemic chemotherapy immediately after surgery in patients with suspected high-risk non-muscle-invasive bladder cancer NMIBC. This type of bladder cancer often recurs, and residual tumors or floating tumor cells after standard surgery may increase this risk. The study aims to see if chemotherapy given within 24 hours after tumor removal can reduce recurrence and improve patient outcomes.
Participants will receive chemotherapy with cisplatin and gemcitabine through an intravenous infusion within 24 hours after their transurethral resection of bladder tumor TURBT surgery. Fluid samples will be collected before and after surgery and chemotherapy to assess tumor changes. Following this, patients will undergo one year of intravesical Bacillus Calmette-Gurin BCG treatment according to guidelines, with regular imaging and cystoscopic exams to monitor their condition.
Throughout the study, researchers will monitor recurrence-free survival over one year, pathological changes 2-6 weeks after chemotherapy, and any serious side effects. They will also evaluate chromosomal instability using UroCAD testing around 15 days post-surgery. Participants will be closely followed with imaging and bladder examinations, with the total follow-up period lasting approximately two years to assess long-term effects and safety.
CONDITIONS
Brief Title
Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
Research Team
S
Shuxiong Zeng, M.D. Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients with a history and cystoscopy results indicating high-risk NMIBC, including high-grade T1, any recurrent high-grade Ta, high-grade Ta with tumor diameter greater than 3 cm or multifocal, any CIS, any BCG failure in patients with high-grade disease, any variant histology, any LVI, or any high-grade prostatic urethral involvement
Patients in generally good condition with a follow-up period of 2 years
Age 18 years or older
You will not qualify if you...
Bladder cancer other than urothelial carcinoma
Muscle-invasive bladder cancer or benign diseases
Incomplete tumor resection
Active infection
Concurrent upper urinary tract or prostatic urethral urothelial carcinoma
Previous systemic chemotherapy, immunotherapy, or radiotherapy
Leukopenia or thrombocytopenia
Serum creatinine greater than twice the normal level
Uncontrollable urinary tract infection
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Within 24 hours after surgery
Participants receive systemic chemotherapy with cisplatin and gemcitabine via intravenous infusion within 24 hours after transurethral resection of bladder tumor (TURBT).
1 visit (in-person)
Treatment
Duration - 1 year
Following the immediate chemotherapy, participants undergo 1 year of intravesical Bacillus Calmette-Guérin (BCG) induction and maintenance therapy with regular imaging studies and cystoscopic examinations to assess pathological response.
Regular visits for imaging and cystoscopy during therapy
Follow-up
Duration - About 2 years
Participants are followed for up to 2 years after the first chemotherapy to monitor recurrence-free survival and adverse events.
Periodic follow-up visits for assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Comparing 1-Year Recurrence After Modified En Bloc Resection ERBT Versus Transurethral Resection TURBT for Large Bladder Tumors Larger Than 2.5 cm
Bladder-Sparing Treatment Approach for Large Non-Muscle-Invasive Bladder Cancer
Comparing Maximal TURBT with Chemotherapy and Immunotherapy Versus Immediate Radical Cystectomy
Multicenter Study Monitoring Recurrence of Urothelial Carcinoma Using Urine Microscopic Residual Disease Detection
Phase 1 Study Evaluating Safety and Pharmacokinetics of Intravesical UGN-501 in Adults with Recurrent Non-Muscle Invasive Bladder Cancer
Phase III Study Comparing Intravesical SHR-1501 Plus BCG to Chemotherapy in Adults With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Phase 3 Study of Disitamab Vedotin Combined with BCG Versus BCG Alone in Adults with HER2-Positive, High-Risk Non-Muscle-Invasive Bladder Cancer
Feasibility Study of Laser-Based Distance Control Using the ATLAS System in Patients With Superficial Bladder Tumors
Study of Immediate Cisplatin and Gemcitabine Chemotherapy After Surgery for High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 2 Study of RC48-ADC Intravenous and Gemcitabine Bladder Instillation in Adults with High-Risk Non-Muscle-Invasive Bladder Cancer Who Are BCG Naive or BCG Unresponsive and Have HER2 Expression
Phase 12 Study of Intravesical Recombinant Mycobacterium BCG for Adults with Non-Muscle Invasive Bladder Cancer Eligible for Tice BCG Treatment
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
Edward M Messing, Catherine M Tangen, Seth P Lerner...
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Christian Pfister, Gwenaelle Gravis, Aude Flechon...
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Judith Bosschieter, Jakko A Nieuwenhuijzen, Tessa van Ginkel...